ERVA Report | Engineering Opportunities to Combat Antimicrobial Resistance
Engineering-directed research and technologies are needed to bridge the gap between patient needs and clinical translation. The priorities discussed in this report describe the innovative research needed to prevent or halt the progression of AMR and its consequences in the lives
of patients. Engineering research enabling new preventive and therapeutic approaches can significantly contribute to addressing this global challenge.
Research into the following overarching areas is needed to generate and implement novel solutions that treat AMR-related infections and prevent the future development and spread of AMR:
- Diagnostic Biosensors and Wearables
- Engineered Antimicrobial Surfaces
- Smart Biomaterials
- Cell Engineering for Drug-Free Approaches
- Advanced Modeling Approaches
There is an urgent need to identify and implement novel solutions that treat AMR-related infections and prevent the future development and spread of AMR. At the Feb. 6-7, 2024 visioning event convened by ERVA, 55 researchers, industry leaders, and policymakers representing a broad range of expertise met to create a roadmap of innovative, less-explored lines of multidisciplinary engineering research that can transform efforts to mitigate AMR. This report illuminates the engineering priorities identified during this event, and aims to inspire researchers and funders (public, private, and nonprofit) to support and pursue them.
The Engineering Research Visioning Alliance (ERVA) is funded by the National Science Foundation Directorate for Engineering under a cooperative agreement administered by UIDP. Its mission is to identify and develop bold and transformative new engineering research directions and to catalyze the engineering community’s pursuit of innovative, high-impact research that benefits society. Learn more at ervacommunity.org.